This listing of the claims will replace all previous versions:

1. (withdrawn) A method for the introduction of the production of TGF-β1 and of the expression of TGF-β1 in and/or on Treg cells comprising utilizing one inhibitor or of several inhibitors of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity for the induction of the production of TGF-β1 and of the expression of TGF-β1 in and/or on Treg cells.

2. (withdrawn) The method according to claim 1, wherein the one inhibitor or the several inhibitors of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity is/are at least one member selected from the group consisting of actinonin, leuhistin, phebestin, amastatin, bestatin, probestin, arphamenin, MR 387, β-amino thiols, α-amino phosphinic acids and their esters and their salts, α-amino phosphonats, α-amino boronic acids, α-amino aldehydes, hydroxamates of α-amino acids, N-phenyl phthalimides, N-phenyl homophthalimides, α-ketoamides, thalidomide and its derivatives.

3. (withdrawn) The method according to claim 2, wherein, as the one inhibitor or the several inhibitors, α-ketaomides, preferably 3-amino-2-oxo-4-phenylbutanoic acid amides, α-amino phosphinic acids, preferably D-Phe-γ[PO(OH)-CH_2]-Phe-Phe, N-phenyl homophthalimides, preferably PAQ-22, α-amino phosphonates, preferably RB3014 and/or phebestin, particularly preferably PAQ-22, RB3014 and/or phebestin is/are used.

4. (withdrawn) The method according to claims 1, wherein cytosolic alanyl aminopeptidase serves as the enzyme having a similar substrate specificity.

5. (withdrawn) The method according to claim 4, wherein PAQ-22 is used as the one inhibitor or wherein the several inhibitors comprise PAQ-22.

6. (currently amended) A method for preventing and/or treating autoimmune diseases comprising ~~utilizing~~ administering to an individual in need of treatment a composition comprising one inhibitor or ~~of~~ several inhibitors of alanyl aminopeptidases and / or of

enzymes having a similar substrate specificity for preventing and/or treating autoimmune diseases, wherein the administration to the individual results in the prevention and/or treatment of the autoimmune diseases.

7. (currently amended) The method according to claim 6, wherein the autoimmune disease is selected from the group consisting of ~~for preventing and/or treating~~ rheumatoid arthritis, Lupus Erythematodes, multiple sclerosis, IDDM, Morbus Crohn, Colitis Ulcerosa, psoriasis, neurodermatosis, glomerulonephritis, interstitial nephritis, vasculitis, autoimmune diseases of the thyroid gland, autoimmunehemolytic anemia or other chronic diseases having an inflammatory genesis as, for example, arteriosclerosis.

8. (cancelled)

9. (withdrawn) A method for preventing and/or treating allergies comprising utilizing one inhibitor or of several inhibitors of alanyl aminopeptidases and or of enzymes having a similar substrate specificity for preventing and/or treating allergies of the type I (according to Gell and Coombs), hay fever or allergies of the type II, III or IV.

10. (currently amended) ~~The use according to claim 9~~ A method for preventing and/or treating bronchial asthma or hay fever as allergies of the type I (according to Gell and Coombs), and/or contact allergies as allergies of the types II, III or IV, the method comprising administering to an individual in need of treatment a composition comprising one inhibitor or several inhibitors of alanyl aminopeptidases and or of enzymes having a similar substrate specificity for preventing and/or treating autoimmune diseases, wherein the administration to the individual results in the prevention and/or treatment of one or more of said allergies.

11. (currently amended) A method for suppressing graft rejections comprising ~~utilizing~~ administering to an individual, wherein the individual has received or is expected to receive a tissue graft, one inhibitor or several inhibitors of alanyl aminopeptidases and or of enzymes having a similar substrate specificity for suppressing graft rejection reactions,

wherein the administration to the individual results in suppression of rejection of the tissue graft.

12.-16. (cancelled)

17. (withdrawn) The method according to claim 1, wherein peptide fragments of pathogenic autoantigens or synthetic analogs and/or specific antigenic components of pathogenic microorganisms are used in addition.

18.-19. (cancelled)

20. (withdrawn) A medicament or pharmaceutical preparation method comprising utilizing one inhibitor or several inhibitors of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity for the preparation of a medicament or of a pharmaceutical preparation for the induction of the production of TGF-β1 and of the expression of TGF-β1 in and/or on Treg cells.

21.-24. (cancelled)

25. (withdrawn) A medicament or pharmaceutical preparation method comprising utilizing one inhibitor or several inhibitors of alanyl aminopeptidases and or of enzymes having a similar substrate specificity for the preparation of a medicament or of a pharmaceutical preparation for preventing and/or treating autoimmune diseases.

28. (withdrawn) A medicament or pharmaceutical composition preparation method comprising utilizing one inhibitor or several inhibitors of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity for the preparation of a medicament or of a pharmaceutical composition for preventing and/or treating allergies of the type I (according to Gell and Coombs), hay fever or allergies of the type II, III or IV.

29. (cancelled)

30. (withdrawn) A medicament or pharmaceutical preparation method comprising utilizing one inhibitor or several inhibitors of alanyl aminopeptidases and or of enzymes having a similar substrate specificity for the preparation of a medicament or of a pharmaceutical preparation for suppressing graft rejection reactions.

31.-38. (cancelled)

39. (withdrawn) Pharmaceutical preparation, comprising one inhibitor or of several inhibitors of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity as well as one or several pharmacologically unobjectionable carrier, additive and/or auxiliary substance(s).

40. (withdrawn) Pharmaceutical preparation, comprising one inhibitor or several inhibitors of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity and peptide fragments of pathogenic autoantigens or synthetic analogs and/or specific antigenic components of pathogenic microorganisms as well as one or several pharmacologically unobjectionable carrier, additive and/or auxiliary substance(s).

41. (new) The method according to claim 6 or claim 7, wherein the inhibitor of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity is selected from the group consisting of actinonin, leuhistin, phebestin, amastatin, bestatin, probestin, arphamenin, MR 387, β-amino thiols, α-amino phosphinic acids and their esters and their salts, α-amino phosphonats, α-amino boronic acids, α-amino aldehydes, hydroxamates of α-amino acids, N-phenyl phthalimides, N-phenyl homophthalimides, α-ketoamides, thalidomide and its derivatives.

42. (new) The method according to claim 10, wherein the inhibitor of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity is selected from the group consisting of actinonin, leuhistin, phebestin, amastatin, bestatin, probestin, arphamenin, MR 387, β-amino thiols, α-amino phosphinic acids and their esters and their salts, α-amino phosphonats, α-amino boronic acids, α-amino aldehydes,

hydroxamates of α-amino acids, N-phenyl phthalimides, N-phenyl homophthalimides, α-ketoamides, thalidomide and its derivatives.

43. (new) The method according to claim 11, wherein the inhibitor of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity is selected from the group consisting of actinonin, leuhistin, phebestin, amastatin, bestatin, probestin, arphamenin, MR 387, β-amino thiols, α-amino phosphinic acids and their esters and their salts, α-amino phosphonats, α-amino boronic acids, α-amino aldehydes, hydroxamates of α-amino acids, N-phenyl phthalimides, N-phenyl homophthalimides, α-ketoamides, thalidomide and its derivatives.

It is believed no fee is due with this communication. If any fee is due it may be charged to Deposit Account no. 08-2442.

Respectfully submitted,
Hodgson Russ LLP

By _____
John D. Lopinski, Reg. No. 50,846

One M&T Plaza, Suite 2000
Buffalo, New York 14203-2391
Tel:(716) 848-1430
DATE: September 8, 2006

013183/00044 BFLODOCS 1648096v1